Avail is conducting a Phase 2, randomized clinical study to evaluate the efficacy and safety of a new drug in female Subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
Avail Clinical is conducting an 11-week, Phase 2 Multicenter, Randomized, Double−Blind, Parallel−Group, Placebo−Controlled Study of a new drug in Subjects with Fibromyalgia (FM).
A randomized, double-blind, placebo-controlled Phase III Trial to evaluate immunogenicity and safety of three consecutive production lots of the IMVAMUNE® smallpox vaccine in healthy subjects.
This study is a Phase 1, Placebo-Controlled, Randomized Trial to Assess the Safety and Tolerability of a New Drug in Obese Hyperlipidemic Adults with or without Type 2 Diabetes.
This study is a Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial to Assess the Safety, Tolerability and Immunogenicity of a new Meningococcal Vaccine When Given in Healthy Subjects Age 11 to 26.
The primary objective of this study is to evaluate the 24-hour spirometric effect (FEV1) of a new drug over a 12-week treatment period in subjects with COPD.
The primary objective of this study is to evaluate the efficacy of a new drug compared with a placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe Chronic Lower Back Pain.
The primary objectives of this study are to evaluate the 12-week safety, antiviral activity and tolerability of this new Hep C drug when given in combination with PEG and RIBA as measured by extended rapid virologic response.
Satisfied Users & 
Approved Press Releases
